Viking Therapeutics Climbs After Fatty Liver Disease Results

(Bloomberg) -- Viking Therapeutics jumped 14 percent pre-market Wednesday after an abstract of its experimental fatty liver disease drug, VK2809 was released ahead of the International Liver Congre...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.